DMK Pharmaceuticals Corporation

DMKP.Q

US00547W3079

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 12:47:05 29/06/2024 am IST			5-day change	1st Jan Change
0.0293 ^USD	0.00%		-17.93%	-95.82%

20/06	ZMI Pharma, Inc acquired Automated assembly systems, all patents, inventory of DMK Pharmaceuticals Corporation.	CI
14/06	First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation	CI

ZMI Pharma, Inc acquired Automated assembly systems, all patents, inventory of DMK Pharmaceuticals Corporation.

June 20, 2024

ZMI Pharma, Inc acquired Automated assembly systems, all patents, inventory of DMK Pharmaceuticals Corporation on June 20, 2024. The transaction has been approved by bankruptcy court.

ZMI Pharma, Inc completed the acquisition of Automated assembly systems, all patents, inventory of DMK Pharmaceuticals Corporation on June 20, 2024.

Latest news about DMK Pharmaceuticals Corporation

ZMI Pharma, Inc acquired Automated assembly systems, all patents, inventory of DMK Pharmaceuticals Corporation.	20/06	CI
First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation	14/06	CI
Motion for Case Conversion Filed by DMK Pharmaceuticals Corporation	11/06	CI
First Motion for Exclusivity Period Extension Filed by DMK Pharmaceuticals Corporation	30/05	CI
Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation	08/05	CI
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	11/04	DJ
North American Morning Briefing : Focus Turns to -2-	04/04	DJ
Bidding Procedure Approved for DMK Pharmaceuticals Corporation	04/04	CI
Motion for Asset Sale Filed by DMK Pharmaceuticals Corporation	21/03	CI
DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index	08/02	CI
Motion for Joint Administration Approved for DMK Pharmaceuticals Corporation	06/02	CI
DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) dropped from NASDAQ Composite Index	06/02	CI
Motion for Joint Administration Filed by DMK Pharmaceuticals Corporation	02/02	CI
DMK Pharmaceuticals Corporation Filed for Bankruptcy	02/02	CI
DMK Pharmaceuticals Corporation Announces Board Appointments	01/02	CI
Maxim Starts DMK Pharmaceuticals With Buy Rating, $1.50 Price Target	07/12	MT
DMK Pharmaceuticals Corporation Regains Full Rights from US WorldMeds for SYMJEPI	28/11	CI
DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) added to NASDAQ Composite Index	21/11	CI
Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from NASDAQ Composite Index	20/11	CI
Earnings Flash (DMK) DMK PHARMACEUTICALS CORPORATION Reports Q3 Revenue $9,062	14/11	MT
DMK Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
DMK Pharmaceuticals Corporation Announces CFO Changes	20/23/20	CI
DMK Pharmaceuticals Corporation Announces Executive Changes	20/23/20	CI
Jerald Hammann Submits Shareholder Proposals to DMK Pharmaceuticals	13/23/13	CI
Jerald Hammann Submits Shareholder Proposals to DMK Pharmaceuticals	03/23/03	CI

Chart DMK Pharmaceuticals Corporation

Duration

Period

More charts

Company Profile

DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Companyâs commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Companyâs lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Companyâs other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinsonâs disease.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
DMK PHARMACEUTICALS CORPORATION	-95.82%	296K
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B

Other Pharmaceuticals

DMK Pharmaceuticals Corporation

Equities

DMKP.Q

US00547W3079

Pharmaceuticals

ZMI Pharma, Inc acquired Automated assembly systems, all patents, inventory of DMK Pharmaceuticals Corporation.

Latest news about DMK Pharmaceuticals Corporation

Chart DMK Pharmaceuticals Corporation

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals